Printer Friendly

Timing of levosimendan in cardiac surgery/Kardiyak cerrahide levosimendan kullaniminda zamanlama.


Surgical manipulations, underlying cardiac disease, ischemia and reperfusion are predominant causes of cardiac dysfunction encountered after cardiopulmonary bypass (CPB). Endothelin-1 secreted during CPB, has coronary vasoconstrictive and C3a has negative inotropic and strong chemotactic effects.

During reperfusion, activated neutrophils adhere to cardiac myocytes and endothelial cells by MAC-1 adhesion receptors (1, 2). Activated neutrophils lead to the release of cytokines and free oxygen (02) radicals. Extracorporeal circulation increases the myocardial edema. The most important reasons for this increase are reduction in the osmotic pressure of plasma colloids, high coronary perfusion pressure, distension of the ventricles and ventricular fibrillation. Loss of contractility during ventricular fibrillation may result in a decreased lymphatic flow through the heart. Moreover, antibodies that develop against MAC-1 receptors also could leadto neutrophil adhesion, diastolic dysfunction and myocardial edema. Myocardial stunning inevitably occurs during cross clamping. These factors lead to temporal abnormalities in cardiac function during the early stage of the surgery (1). Thus, there is a general requirement for the use of inotropic agents in order to facilitate weaning off from CPB and maintain sufficient cardiac output (CO).

Most inotropes used in the clinics function by increasing the levels of cytosolic calcium ([Ca.sup.+2]), whereas LS stimulates myocardial contractility without raising the intracellular [Ca.sup.+2] concentration (2,3). Levosimendan increases the [Ca.sup.+2] response to myofilament by binding to cardiac troponin C. As a result, myocardial contraction increases without a higher myocardial 02 consumption (3,4,5). Levosimendan also exhibits vasodilatory effect through the activation of adenosine triphosphatedependent potassium (K+) channels (6, 7). Levosimendan is distinguished from other inotropic agents by this dual mechanism and considered as a good choice in high-risk patients undergoing cardiac surgery (8-10). However, few is known on timing of LS during cardiovascular surgery.

In this retrospective study, we aimed to determine the best timing of the administration of LS in high-risk patients who underwent cardiovascular surgery.


A total of 15 consecutive patients, who underwent open heart surgery in Cardiovascular Surgery Clinic between March 2005 and March 2007 were administered LS during various stages of the procedure, were investigated retrospectively. Our first experience with LS was about usage of LS in cardiac failure at the postoperative period. In the next 5 cases we used LS in the patients with early usage claim of LS and those had difficulties with ending the pump, afterwards we thought we can get better results with using LS before pump, so we used LS after induction in 5 patients.

The patients were divided into three groups according to their timing of LS use; five patients who received LS infusion following the induction of anesthesia formed Group 1, five patients who received LS infusion during the pump removal formed Group 2 and five patients who received LS infusion during the post-operative period formed Group 3.

The method of anesthesia was equally applied to all cases. Induction of anesthesia was provided through titration of 2 mg of midazolam i.v., 2-5 [micro]g kg-1 of fentanyl i.v. and 3-5 mg [kg.sup.-1] of thiopental sodium i.v. Muscle relaxation was achieved by 0.1 [micro]g [kg.sup.-1] pancuronium bromide and anesthesia was maintained by high dose fentanyl. Hemodynamic measurements were performed by using the thermodilution method, by the placement of pulmonary artery catheter after induction of anesthesia.

Levosimendan infusion was administered to all patients at a rate of 0.1 [micro][g.sup.-1] [kg.sup.-1]min without a loading dose. At the end of the CPB, dopamine infusion was initiated in cases with a mean arterial pressure (MAP) [less than or equal to] mmHg within the adequate perfusion period; other inotropic agents were added in cases with MAP [less than or equal to]60 mmHg and pulmonary capillary wedge pressure (PCWP)[greater than or equal to] 15 mmHg. During the post-operative period, when hemodynamic stability was maintained the inotropic agents were ceased, by reducing the dosage. An intra-aortic balloon pump (IABP) was applied when there was a pump insufficiency despite inotropic support with dopamine, dobutamine, adrenalin treatment and LS infusion.The measurements were performed priorto LS infusion and after 24 hours.

The age and genderof patients, type of operation, preoperative features, duration of aortic cross-clamp, the total duration of perfusion, duration of the operation, preoperative ejection fraction (EF) and hemodynamic data [MAR mean pulmonary artery pressure (MPAP), pulmonary capillary wedge pressure (PCWP), cardiac index (CI)], doses of inotropic agents, postoperative (24 hours) urine output, and lactate levels before and after LS were registered and compared.

Statistical analysis

Statistical analyses were performed using SPSS software version 13.0 (SPSS Inc. Chicago, IL, USA). Normal distribution of data was checked with Shapiro-Wilk test. Continuous variables were expressed as mean [+ or -] SD and categorical variables were presented as number of patients. Due to the fact, that measured data of inotrope consumption were markedly skewed, values are expressed as median, first and third quartiles. Categorical variables were compared with Fisher exact tests. Continuous variables and inotrope consumptions were compared with Kruskal- Wallis analysis. Mann Whitney U test was used to find differences while comparison of 2 groups. Comparison analyses between before and after LS values were made by using Wilcoxon rank test. A p value of <0.05 (2-tailed) was considered as significant.


When the patients separated into three groups according to the starting time for LS were compared no significant differences were determined between the groups with regards to age, gender, preoperative EF duration of the operation, duration of cross clamp and the total duration of perfusion (p>0.05) (Table 1).

Comparison of hemodynamic effects of LS showed statistically significant differences between the 1st and 2nd measurements of the MAP in Group 1 and Group 2. Although a difference was found between the measurements in Group 3, this difference was not statistically significant. (p>0.05) (Table 2). There were statistically significant differences between the 1st and 2nd measurements of the MPAP in Group 2 and Group 3. The difference between these measurements in Group 1 was not statistically significant. (p>0.05) (Table 2). The PCWP decreased in all groups (p<0.05), while CI significantly increased after LS infusion (p<0.05) (Table 2). No statistically significant differences between groups were found in MAR MPAR PCWP and CI values between before and after LS treatment. There was a statistically significant difference in lactate levels before LS between Groups 1 and 3 (p<0.05) (Table 2). The differences in lactate levels before and after LS in all groups were not statistically significant (p>0.05) (Table 2). No statistically significant difference was verified between the three groups according to postoperative urine output (p>0.05) (Table 2).

The usage of inotropic agents in all of our patients was inevitable. While in groups 1 and 2 all inotropic agents could be stopped after 24 hours, in Group 3 no regression could be established in the inotropic posology, with exception of one patient (Table 3). There was no statistically significant difference between the 1st and 2nd measurements of each of the three inotropic agents in Group 3 (p>0.05) (Table 3).

During the post-operative period, IABP was applied to one patient of groups 1 and 2, whereas it was applied to four patients in Group 3 (p=0.08) (Table 1).


In our retrospective study, adequate urine output, increased CI and decreased PCWP were observed in all of our patients who underwent cardiac surgery and having poor left ventricular function. The MPAP was decreased in LS administered patients during pump removal period and post-operative period. Twenty-four hours after LS application, whereas all inotropic agents could be stopped in Group 1 and 2, in Group 3 inotropic infusion could not be stopped. As a result, we observed that use of LS during intraoperative and pump removal periods was effective.

The frequency of low-output syndrome following cardiac surgery is 3-10% (7). Following the cardiac surgery, the ratio of patients who require positive inotropic support after CPB is 32.4% (13). The ratio of patients who require positive inotropic support during and after CPB and CABG with preoperative EF<30was92% (4, 12). When our patientgroups were examined, it was verified that all of them were composed of high-risk patients.

Levosimendan has superior pharmacologic features when compared to conventional inotropic agents. It enhances the sensitivity of myofilaments to calcium during cardiac systole by calcium dependent binding to troponin C. This interaction strengthens the actin-myosin cross-bridges through the stabilization of calcium-induced conformational changes in tropomyosin. Levosimendan accomplishes this effect by enhancing the intracellular [Ca.sup.+2] sensitivity of troponin C without increasing the intracellular [Ca.sup.+2] concentrations (3,15-18). Since LS does not increase intracellular [Ca.sup.+2] levels, its arrhythmogenic potential is reported to be low (3,19). The hemodynamic effects of LS were found to be higher in patients who used p-blockers. Its superiority over other inotropic agents can also be evidenced with this feature (20).

In the latest guideline of the European Society of Cardiology, LS is recommended for the diagnosis and treatment of heart failure with low cardiac output secondary to cardiac systolic dysfunction. On the other hand, there is still limited evidence regarding the use of LS in postoperative myocardial dysfunction (21). However, publications concerning the use of LS in cardiac surgery are raising in parallel to our experience.

Levosimendan, a new inodilator used in the treatment of decompensated heart failure, has been reported to be effective in patients with high perioperative risks, with abnormal left ventricular function, and who face difficulties in weaning off cardiopulmonary bypass (3). It can be used during various stages of cardiac surgery. Rajek et al. (22) reported the first case of LS application in eight patients with congestive heart failure and preoperative left ventricular EF of 19[+ or -]5%, who were planned to undergo elective cardiac surgery. Of these patients, 5 underwent coronary artery bypass surgery, 2--mitral valve replacement and 1 - undergo aortic valve replacement. Levomisendan was administered before sternotomy, after a loading dose of 0.6 [micro][g.sup.-1] kg for 10 minutes, a full maintenance infusion dose of 0.2 [micro]g-1 [kg.sup.-1] min. There was a dramatic increase in cardiac output after 60 minutes following LS infusion, and while there was a decrease in PCWR cardiac output remained above 5 L/min. There was no change in heart rate, MAP and MPAP during LS infusion. On the other hand, it was possible to successfully wean off cardiopulmonary bypass on every patient without the requirement of an IABR and also confirm a decrease in both catecholamine need and permanence in the intensive care unit. There are other publications which confirmed the results of Rajek et al. (3, 7).

In our study, LS infusion was administered in a different from previous studies (22) way to all patients ata rate of 0.1 [micro][g.sup.-1] [kg.sup.-1]min without loading dose. The findings in groups 1 and 2 were similar to results of Rajek et al. (22).

The positive inotropic and cardioprotective effects of LS have been demonstrated in high-risk patients with acute myocardial ischemia who would undergo emergency surgery revascularization (3,23).

Labriola et al. (7) investigated whether LS was effective or not for patients with a low output after cardiac surgery, by administering a loading dose of 12 [micro]g-1 kg in 10 min followed by a continuous infusion dose of 0.1 [micro][g.sup.-1] [kg.sup.-1] min for a period of 12 hours. A combined hemodynamic improvement (increase of more than 30% in CI, improvement in PCWP) was established within three hours after initiating LS infusion in 8 (73%) of the 11 patients with a severe decrease in output and hemodynamic disorder following the surgery. After admission to the intensive care unit, no inotropic drug was initiated in 4 of these patients except LS; however, other inotropic agents were administered to 7 patients. Those who did not receive other inotropic agents were administered LS within four hours following admission to the intensive care unit. Although LS was administered to only 1 patient within two hours after intensive care unit admission, adrenalin was initiated; however, the left ventricular EF of this patient was very low compared to the other patients. Specifically, it was reported that there was a significant increase in CI and stroke volume, and a significant decrease in MAR systemic vascular resistance index, MPAR right atrial pressure and PCWR These changes were associated with the conditions related to improvement in cardiac function - significant decrease in preload and afterload concomitant with a decrease in cardiac output; and as a result it was reported that LS provide better outcomes during the short term treatment of patients with low cardiac output following cardiac surgery. We also oberved good effects of LS on PAR CI, PCWB, MAP and urine output values in the patients received LS in postoperative period. But we determined that inotropic agents could be stopped in Groups I and 2 patients in whom LS infusion was started earlier.

Waris etal. (8) applied a continuous preoperative LS infusion to 8 of the 16 patients underwent cardiac surgery, and continuous postoperative LS infusion to the remaining 8 patients. When the preoperative baseline level of LS infusion was compared to the continuous LS infusion, there was a significant increase in the CI of both groups and no significant change in PCWP and systolic blood pressure. Successful results with LS were obtained in all patients including those who experienced ineffective weaning off CPB with catecholamine, and three deaths were recorded: one high-risk patient in the preoperative group and two patients in the postoperative group. They concluded that LS could be used as a postoperative recovery treatment for patients with difficulties in weaning off CPB, and also that elective initiation of preoperative LS was applicable for high preoperative risk patients or patients with left ventricular dysfunction. They have found that LS usage was also successful in the postoperative period, a different finding from ours. Although we have seen positive changes in most of the parameters in the postoperative use of LS, we determined that using LS following the induction of the anesthesia and pump removal is more effective because of absence of requirements for inotropic agents and the decrease in the need of IABP.

In the prospective, randomized, placebo controlled and double-blinded study of Eriksson et al. (24), which included 3 patients with coronary artery disease and 60 patients with left ventricular EF<50%, LS was administered in 12 [micro]g-1 kg bolus for 10 minutes and, immediately after induction of anesthesia, and was maintained at a dose of 0.2 [micro][g.sup.-1] [kg.sup.-1] min for 23 hours and 50 minutes. They standardized anesthesia, hemodynamic treatment and weaning off CPB, and did not allow additional use of inotropes after induction of anesthesia. If after 10 minutes of weaning off CPB the CI was >2.2 L/min/m2, mixed venous [O.sub.2] [greater than or equal to] 70%, central venous pressure [less than or equal to]12 mmHg and PCWB [less than or equal to] 16 mmHg success was obtained; however, if such was not achieved, CPB was repeated by initiating epinephrine infusion (0.01 [micro][g.sup.-1] [kg.sup.-1]min). An IABP was attached after failure of the second weaning-off trial. The mean time after commencing the weaning off CPB was similar in each of the two groups; primary weaning off was successful in 73% of the patients in the LS group and in 33% of the placebo group. The IABP was required in 4 patients of the placebo group who had two unsuccessful weaning-off attempts, but no patient in the LS groups required IABP As a result, the comparison of LS and placebo revealed that there was a significant increase in primary weaning off CPB and a decrease in the need for additional inotropic or mechanic therapy in LS administration.

As mentioned above, different investigators preferred LS at differenttimes, such as immediately after induction of anesthesia, during pump removal or during the postoperative period; and very favorable results were obtained from all of these.

Tasouli et al. (25) have performed 0.1 [micro][g.sup.-1] [kg.sup.-1]min LS infusion without initially doses as ours in 45 patients in the operating room and intensive care unit in a prospective study. The aim of their study was to compare the LS effect on duration of intensive care unit and hospital stays in association with the timing of its infusion. In their study patients were prospectively selected to receive LS in addition to conventional inotropic support (epinephrine and dobutamine) and IABR The patients were randomized to receive LS in the operating theatre during the operation or in the intensive care unit the second postoperative day. They added simultaneous norepinephrine infusion, when required, to maintain MAP >70 mmHg. They investigated the hemodynamic profile, EF the B-type natriiuretic peptide plasma levels 48 hours after the beginning of LS infusion, the duration of IABP and classical inotropic support, the weaning success from mechanical ventilation and the patients' outcome. The efficacy of LS was identical in both groups with improvement in the hemodynamic and functional status of patients. They found that the intensive care unit stay and hospital stay were significantly decreased in patients who receive LS in operating room compared to patients of intensive care unit group. Consequently they found that, early infusion of LS in patients with compromised cardiac function, immediately after the confirmation of low-output syndrome from the operating theatre, was associated with improved in-hospital outcomes.

In the present study, the most effective time of LS application in cardiac surgery was intended to be determined by dividing the patients into 3 groups retrospectively according to their LS use. Group 1 consisted of patients who used LS from the beginning, Group 2 consisted of patients who used LS during pump removal, and Group 3 consisted of patients who used LS after post-operative 24 hours. Despite inotropic support in all groups, IABP was placed in the case of a pump insufficiency.

During the process, an infusion dose of 0.1 [micro][g.sup.-1] [kg.sup.-1] min was administered without loading dose by taking into consideration the fact that hypotension may occur with bolus doses. In the literature, there are studies regarding timing of LS use; however no such comparison was performed. According to our results, when LS was administered, there was an increase in urine output and CI, and a decrease in MPAP in all groups at the end of LS infusion.

While in groups 1 and 2 all inotropic agents were stopped after 24 hours, in Group 3 no regression could be established in the inotropic posology, except for one patient. During the postoperative period, IABP was applied to one patient of each groups 1 and 2, whereas it was applied to four patients of the Group 3.

Significant increases of CI and urine output, and significant reductions in MPAP and PCWP are the signs of improvement in cardiac function. Early elective initiation of LS in patients with poor left ventricular function at preoperative examination may reduce the inotropic support and the need for IABP by ensuring comfortable weaning-off balloon pump, decreasing the permanence time in the intensive care unit, and ultimately providing a significant reduction in mortality.

In our clinic, we administer LS infusion at a rate of 0.1 [micro][g.sup.-1] [kg.sup.-1]min without a loading dose. Because vasodilator effect of the drug commences first during the application of loading dose, probable hypotension forced us to an application like this as preferred by many researchers. Activity starting in 12 minutes with loading dose appears in much longertimes in solely infusion applied cases. By keeping this in mind, beginning of LS after the induction and during removal from the pump may be more effective according to postoperative use.

Limitations of the study

The major limitation of the study was the small number of cases. Additionally, no application of loading dose and absence of different doses were also the limitations of this study. For this reason, prospective, controlled randomized studies of LS are needed to be urgently performed in more extended series with different loading and maintenance doses and at more different timing periods (e.g. prior to operation).


We suggest that administration of LS to high- risk patients with poor left ventricular function during the cardiac surgery leads to favorable results; however, timing of LS infusion is very important due to its effectiveness at early stages. If one decides to use LS as an inotropic support for patient with severe left ventricular dysfunction, the infusion should be started very early, before CPB and aortic cross-clamp.


(1.) Buket S, Engin C. Uc H. Cardiopulmonary bypass. In: Pac M, editor. Cardiac and vascular surgery. Ankara: MN Medical & Nobel Publishing; 2004. p 115-50 [Turkish].

(2.) Byrne JG, Smith WJ, Murphy MP Couper GS, Appleyard RF, Cohn LH. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg 1992; 104: 1589-96.

(3.) Shahzad GR, Benson SR. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006; 81:1536-46.

(4.) De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766-73.

(5.) Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007; 46: 535-52.

(6.) Yokoshiki H, Katsube Y, Sunagawa N. Levosimendan, a novel Ca+2 sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-59.

(7.) Labriola C, Brigiani MS, Carrata F Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42: 204-11.

(8.) Waris KS, Ylinen RS, Harjola VP Levosimendan in cardiac surgery. J Cardiothorac Vase Anesth 2005; 19: 345-9.

(9.) Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008; 17:1143-50.

(10.) Lehmann A, Boldt J, Lang J, Isgro F, Blome M. Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization? Anesthesiol Intensivemed Notfallmed Schmerzher; 2003; 38: 577-82.

(11.) Avery GJ, Ley SJ, Hill JD, Hershon JJ, Dick SE. Cardiac surgery in the octogenarian: evaluation of risk, cost, and outcome. Ann Thorac Surg 2001;71:591-6.

(12.) Ascione R, Narayan P Rogers CA, Lim KH, Capoun R, Angelini GD. Early and midterm clinical outcome in patients with severe left ventricular dysfunction undergoing coronary artery surgery. Ann Thorac Surg 2003; 76: 793-9.

(13.) Muller M, Junger A, Brau M, Kwapisz MM, Schindler E, Akintiirk H, et al. Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anesthesia record-keeping system. Br J Anaesth 2002; 89: 398-4.

(14.) Rao V, Ivanow J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 1996; 112: 38-51.

(15.) Haikala H, Kaivola J, Nissinen E, Wall P Levijoki J, Linden IB, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan, J Mol Cell Cardiol 1995; 27:1859-66.

(16.) Levijoki JL, Pollesello P Kaivola J, Tilgmann C, Sorsa T, Annila A, et al. Furterevidenceforthe cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000; 32:479-91.

(17.) Pollesello P Ovaska M, Kaivola J, Tilgmann C, Lundstrom K, Kalkkinen N, et al. Binding of a new Ca+2 sensitizer, levosimendan, to recombinant cardiac troponin C: a molecular modeling, fluorescence probe and proton nuclear magnetic resonance study. J Biol Chem 1994; 269: 28584-90.

(18.) Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007; 12:149-56.

(19.) Figgitt DP Gillies PS, Goa KL. Levosimendan. Drugs 2001; 61: 613-27.

(20.) Follath F Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360:196-2.

(21.) Malliotakis PXenikakisT, LinardakisM.HassoulasJ.Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol 2007; 48: 80-8.

(22.) Rajek AM, Koining H, Jelen M, Schiferer A, Hutschala D. Levosimendan, a new Ca-sensitizer in patients with poor left ventricular function undergoing cardiac surgery. Anesthesiology 2003; 99:133 A.

(23.) Lehmann A, Lang J, Boldt J, Isgro F Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. 2004; Med Sci Monit 10: 89-93.

(24.) Eriksson H, Jalonen J, Heikkinen L, Kivikko M, Laine M, Leino K, et al. Levosimendan enhances weaning from cardiopulmonary bypass in patients with compromised heart function after coronary artery bypass graft surgery. Society of cardiovascular anesthesiologist. 29th annual meeting, 2007 Montreal, Canada. Anesth Analg. Supplement 2007; 104:1-123.

(25.) Tasouli A, Papadopoulos K, Antoniou T, Kriaras I, Stavridis G, Degiannis D, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg. 2007; 32: 629-33.

Murat Aksun, Nagihan Karahan, Tayfun Adanir, Gulcin Aran, Ufuk Yetkin*, Tulin Ozturk,

Atilla Sencan, Ugur Ozgurbuz, Ali Gurbuz*

From Clinics of II. Anesthesiology and Reanimation and *Cardiovascular Surgery, Izmir Ataturk Training and Research

Hospital, Izmir, Turkey

Yazisma Adresi / Address for Correspondence: Dr. Murat Aksun, Clinic of Anesthesiology and Reanimation, Izmir Ataturk Training and Research Hospital, Izmir, Turkey Phone: +90 232 244 44 44 Fax: +90 232 243 15 30 E-mail:
Table 1. Demographic and procedural characteristics of patients

Variables              Group 1              Group 2

Age, years        58.00[+ or -]15.34    61.4[+ or -]6.6
                        62.00                59.0
                    (45.00-69.00)         (56.0-68.0)

Male/Female              5/0                  3/2

Ejection          28.00[+ or -]4.47    31.00[+ or -]7.47
fraction, %             25.00                30.00
                    (25.00-32.50)       (25.00 -37.50)

Euroscore,          5.6[+ or -]2.5      6.6[+ or -]2.5
points                   5.0                  8.0
                      (3.5-8.0)            (4.0-8.5)

Cross- clamp       90.2[+ or -]41.4    64.2[+ or -]33.16
duration, min            95.0                72.0
                     (50.5-127.5)         (32.0-92.5)

Pomp duration,    160.4[+ or -]61.2    102.6[+ or -]44.3
min                     153.0                108.0
                    (108.0-216.5)        (62.5-140.0)

Operation         280.0[+ or -]61.2    213.0[+ or -]52.6
duration, min           280.0                210.0
                    (225.0-335.0)        (165.0-262.5)

Type of operation

CABG, n                   3                    2

CABG+AVR, n               0                    0

AVR, n                    1                    1

AVR+MVR, n                0                    0

Redo AVR, n               1                    0

Redo MVR, n               0                    2

Diabetes                  0                    1
Mellitus, n

COPD, n                   1                    2

IABP use, n               1                    1

Hypertension, n           2                    1

Ml suffered, n            2                    2

Mortality, n              2                    2

Variables              Group 3        Chi-square    P *

Age, years        61.8[+ or -]10.3       0.02      0.99

Male/Female              3/2                       0.26

Ejection          31.00[+ or -]5.48      1.19      0.55
fraction, %             30.00

Euroscore,         5.4[+ or -]1.9        0.89      0.64
points                   6.0

Cross-clamp       81.0[+ or -]28.8       1.34      0.51
duration, min           90.0

Pomp duration,    143.2[+ or -]42.2      3.02      0.22
min                     150.0

Operation         266.0[+ or -]45.7      3.64      0.16
duration, min           270.0

Type of operation                                    P

CABG, n                   2                        0.765

CABG+AVR, n               1                        0.343

AVR, n                    0                        0.562

AVR+MVR, n                1                        0.343

Redo AVR, n               0                        0.343

Redo MVR, n               1                        0.282

Diabetes                  0                        0.34
Mellitus, n

COPD, n                   1                        0.71

IABP use, n               4                        0.08

Hypertension, n           2                        0.74

Ml suffered, n            1                        0.74

Mortality, n              5                        0.08

Data are presented as the mean [+ or -] SD, median (25%-75%) values
and proportions * Kruskal-Wallis test for comparison of continuous
variables and Fisher exact test for comparison of categorical
variables AVR-aortic valve replacement, CABG-coronary artery bypass
surgery, COPD-chronic obstructive pulmonary disease, IABP-intraaortic
balloon pump, Ml-myocardial infarction, MVR-mitral valve replacement

Table 2. Hemodynamic parameters of patients

Variables                Group 1             Group 2

MAR mm Hg

Before LS            65.0[+ or -]9.3     62.8[+ or -]16.0
                          66.0                 65.0
                       (55.5-74.0)         (48.00-76.5)

After LS           76.4[+ or -]([PSI])   74.8[+ or -]12.6
                        (p=0.043)        ([PSI])(p=0 042)
                    76.0 (65.0-88.0)           80.0

PAR mm Hg

Before LS            26.4[+ or -]9.7     30.8[+ or -]17.2
                          25.0                 24.0
                       (18.5-35.0)         (16.0-49.0)

After LS            22.4[+ or -]11.3     19.0[+ or -]7.0
                          22.0           ([PSI])(p=0.043)
                       (12.5-32.5)             18.0

Before LS            18.4[+ or -]7.1     15.4[+ or -]2.1
                          15.0                 15.0
                       (13.5-25.0)         (13.50-17.5)

After LS             11.2[+ or -]2.8      8.8[+ or -]1.9
                    ([PSI])(p=0-043)     ([PSI])(p=0.042)
                          12.0                 8.0
                       (8.5-13.5)           (7.5-10.5)

CI, l/min/[m.sup.2]

Before LS           2.22[+ or -]0.22     2.08[+ or -]0.46
                          2.30                 1.80
                       (2.00-2.85)         (1.75-2.55)

After LS            3.56[+ or -]0.74     3.14[+ or -]0.89
                    ([PSI])(p=0 043)     ([PSI])(p=0.043)
                          3.40                 3.20
                       (2.90-4.30)         (2.30-3.95)

Lactate, mmol/L

Before LS           1.68[+ or -]0.84     3.16[+ or -]1.29
                          1.70                 3.00
                       (1.00-2.35)         (2.10-4.30)

After LS            2.64[+ or -]1.16     2.18[+ or -]0.63
                          2.50                 2.50
                       (1.60-3.75)         (1.50-2.70)

Urine output, ml    3924[+ or -]1125     2620[+ or -]1245
                          3920                 3000
(2900-4950) (1380-3670)

Variables               Group 3         Chi-square    P

MAR mm Hg

Before LS           66.0[+ or -]13.9       0.02      0.99

After LS            81.0[+ or -]7.4        0.46      0.79
PAR mm Hg

Before LS           24.6[+ or -]7.4        0.01      0.99

After LS            20.2[+ or -]7.7        0.08      0.96

Before LS            162[+ or -]23         0.38      0.82

After LS            11.0[+ or -]2.3        3.46      0.18

CI, l/min/[m.sup.2]

Before LS           2.22[+ or -]0.22       1.42      0.49

After LS            2.72[+ or -]0.23       3.03      0.22

Lactate, mmol/L

Before LS          3.46[+ or -]0.92 *      6.96      0.03

After LS            3.08[+ or -]0.55       2.65      0.26

Urine output, ml    2380[+ or -]1435       3.62      0.16

Data are presented as the mean value [+ or -] SD and median (25%-75%)
values Kruskal Wallis test for comparison of variables between 3
groups * Mann Whitney U test-p=0.009 as compared with group 1 ([PSI])
Wilcoxon rank test for intragroup comparison before and after
levosimendan treatment CI-cardiac index, LS-levosimendan, MAP-mean
arterial pressure, PAP-pulmonary arterial pressure, PCWP-pulmonary
capillary wedge pressure

Table 3. Inotrope consumption

Variables   Group 1       Group 2        Group 3         square   P

Dopamine, [micro][g.sup.-1][kg.sup.1]min

Before LS   15.00         15.00          15.00           1.07     0.58
            (12.5-20.0)   (8.75-17.5)    (12.5-20.0)

After LS    O ([PSI])     O ([PSI])      10(5-17.5) *    9.91     0.007

Dobutamine, [micro][g.sup.-1][kg.sup.-1]min

Before LS   15.0          15.0           20.0            4.82     0.09
            (5.0-17.5)    (5.0-17.5)     (20.0-17.5)

After LS    0             0              15(5-20) *      9.91     0.007

Adrenaline, [micro][g.sup.-1][kg.sup.-1]min

Before LS   0(0-0.25)     0.1 (0-0.45)   0.50            5.824    0.054

After LS    0             0              0.40            9.882    0.007
                                         (0.15-0.65) *

Data are presented as the mean value [+ or -] SD and median (25%-75%)
values Kruskal Wallis test for comparison of variables between 3 groups
* Mann Whitney U test - p=0.04 as compared with groups 1 and 2
([PSI]) Wilcoxon rank test for intragroup comparison before and after
levosimendan treatment- p=0.03
COPYRIGHT 2009 Aves Yayincilik
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Investigation/Ozgun Arastirma
Author:Aksun, Murat; Karahan, Nagihan; Adanir, Tayfun; Aran, Gulcin; Yetkin, Ufuk; Ozturk, Tulin; Sencan, A
Publication:The Anatolian Journal of Cardiology (Anadolu Kardiyoloji Dergisi)
Article Type:Report
Date:Jun 1, 2009
Previous Article:Pulmonary artery banding operation and results of terminal biventricular and univentricular repair/Pulmoner arter bant ameliyati ve sonrasinda...
Next Article:Clopidogrel resistance/Klopidogrel direnci.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters